RxDoctor Payments Data

Vinod Valiveti, MD

Geriatric Medicine · Oxnard, CANPI 1598714107

Payments from drug & device makers

$694in general payments, 2019–2025

Across 14 payments — averaging $49.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$349
  • Edwards Lifesciences$166
  • Teva Pharmaceuticals USA, Inc.$47
  • Neurocrine Biosciences, Inc.$34
  • Sunovion Pharmaceuticals Inc.$27
  • Avanir Pharmaceuticals, Inc.$26
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$694100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$694 in reported general payments places this provider in the 70th percentile of 494 geriatric medicine providers in California.

See all geriatric medicine providers in California

Medicare billing

Part B allowed, 2024
$302,879
Medicare patients
577
Services billed
2,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban619$164,491
XareltoRivaroxaban167$42,502
XifaxanRifaximin40$41,047
JanuviaSitagliptin Phosphate125$33,613
EntrestoSacubitril/Valsartan65$19,470
RexultiBrexpiprazole12$18,846
JardianceEmpagliflozin52$15,714
DapagliflozinDapagliflozin Propanediol56$15,036
Atorvastatin Calcium891$14,501
Spiriva RespimatTiotropium Bromide25$13,404
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$13,295
Tiotropium Bromide26$12,841
EpogenEpoetin Alfa31$12,243
Gabapentin666$11,888
TradjentaLinagliptin51$11,778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$22$7,30027 claims
AstraZenecaFarxiga$11$5,76820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 494 geriatric medicine providers in California.

Other geriatric medicine in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →